Double-Team strategy tested for Tough-to-Treat cancer
NCT ID NCT03457948
Summary
This study is testing if combining an immunotherapy drug (pembrolizumab) with a targeted radiation treatment or a procedure to treat liver tumors works better for people with advanced neuroendocrine tumors. The goal is to see if this two-part approach helps the immune system fight the cancer more effectively and shrink tumors. The study is for adults whose cancer has spread to the liver and is causing symptoms or getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.